Hepatitis C and Liver Assessment - Post-SVR Monitoring with Elastography
Australia has made world-leading progress in hepatitis C treatment, but cure does not automatically erase fibrosis risk. Post-SVR monitoring still matters, especially for patients with advanced fibrosis or prior cirrhosis.
Content note
Prepared by the Elastography Australia clinical education team for informational purposes and pathway literacy. It is not patient-specific medical advice.
- Post-SVR patients may improve substantially, but fibrosis regression is not immediate or universal.
- Some patients still require ongoing HCC surveillance despite virologic cure.
- Elastography is valuable because it helps trend recovery and residual risk over time.
Why monitoring continues after cure
The market research highlights Australia’s strong HCV elimination progress, but also the need for ongoing liver assessment in patients who entered treatment with significant fibrosis or cirrhosis.
The central point is that viral cure reduces risk without necessarily resetting the liver to normal immediately.
Fibrosis regression after SVR
Many patients improve after SVR, and elastography is useful for capturing that trajectory. The real clinical value lies in showing whether the liver is stabilising, regressing, or still carrying enough residual risk to justify continued surveillance.
Post-SVR thresholds and surveillance
The practical question after cure is not only whether fibrosis has improved, but whether HCC surveillance and specialist follow-up should continue. That decision is influenced by prior stage, current stiffness trend, and the broader clinical picture.
This is another example of why repeatable, non-invasive assessment is more useful than a one-off answer for many chronic liver disease pathways.
Using elastography over time
Serial elastography gives clinicians a realistic way to monitor regression without sending every patient back into more invasive pathways. In the post-SVR setting, that repeatability is the real advantage.